Pharmacology and Toxicology > Research

Striated Muscle Disease Modeling

Principal Investigator: Dr. med. Malte Tiburcy

About us

Human stem cell models allow for the recapitulation of diseases in the dish. Novel mechanistic insight gained from human tissue engineered models may identify unique therapeutic opportunities. The Tiburcy lab develops human disease models to understand the mechanisms underlying the progression of fatal diseases. The focus is on degenerative heart and skeletal muscle diseases. In close collaboration with the Stem Cell Unit, established jointly by the Institute of Pharmacology and Toxicology and the Clinic for Cardiology and Pneumology at the Heart Center (Herzzentrum) Göttingen, we have created a unique repository for comprehensive disease modelling. The overarching goal is to target the disease causing cell-specific mechanism for pharmacologically induced repair and regeneration.

Principal InvestigatorDr. med. Malte Tiburcy

contact information

telephone: +49 551 3920729
fax: +49 551 395699
e-mail address: m.tiburcy(at)med.uni-goettingen.de

Address

Department of Pharmacology and Toxicology
Robert-Koch-Straße 40
37075 Göttingen

CV
ORCID: 0000-0002-6942-6275

Selected Publications

Shahriyari M, Islam MR, Sakib SM, Rinn M, Rika A, Krüger D, Kaurani L, Gisa V, Winterhoff M, Anandakumar H, Shomroni O, Schmidt M, Salinas G, Unger A, Linke WA, Zschüntzsch J, Schmidt J, Bassel-Duby R, Olson EN, Fischer A, Zimmermann WH, Tiburcy M. Engineered skeletal muscle recapitulates human muscle development, regeneration and dystrophy. J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):3106-3121. doi: 10.1002/jcsm.13094.
Levent E, Noack C, Zelarayán LC, Katschinski DM, Zimmermann WH, Tiburcy M (2020). Inhibition of Prolyl-Hydroxylase Domain Enzymes Protects From Reoxygenation Injury in Engineered Human Myocardium. CIRCULATION. 142(17):1694-1696.[PubMed]
Tiburcy M,Markov, A, Kraemer, LK, Christalla P, Rave-Fraenk M, Fischer HJ, Reichardt HM, Zimmermann WH (2019). Regeneration competent satellite cell niches in rat engineered skeletal muscle. FASEB BIOADVANCES, 1; 731-746.
Tiburcy M, Hudson JE, Balfanz P, Schlick S, Meyer T, Chang Liao ML, Levent E, Raad F, Zeidler S, Wingender E, Riegler J, Wang M, Gold JD, Kehat I, Wettwer E, Ravens U, Dierickx P, van Laake LW, Goumans MJ, Khadjeh S, Toischer K, Hasenfuss G, Couture LA, Unger A, Linke WA, Araki T, Neel B, Keller G, Gepstein L, Wu JC, Zimmermann WH. (2017) Defined Engineered Human Myocardium with Advanced Maturation for Applications in Heart Failure Modelling and Repair. Circulation 135:1832-1847. [PubMed]
Riegler J^§, Tiburcy M^§, Ebert A, Tzatzalos E, Raaz U, Abilez OJ, Shen Q, Kooreman NG, Neofytou E, Chen V, Wang M, Meyer T, Tsao PS, Connolly AJ, Couture LA, Gold JD, Zimmermann WH*, Wu JC*. (2015) Human Engineered Heart Muscles Engraft and Survive Long-Term in a Rodent Myocardial Infarction Model. Circ Res 117:720-739. ^§first authors; *corresponding authors [PubMed]
Godier-Furnémont AFG^§, Tiburcy M^§, Wagner E, Dewenter M, Lämmle S, El-Armouche A, Lehnart SE, Vunjak-Novakovic G, Zimmermann WH. (2015) Physiologic force-frequency response in engineered heart muscle by electromechanical stimulation. Biomaterials 60:82-91. ^§shared authorship. [PubMed]
Tiburcy M, Zimmermann WH. (2014) Modeling myocardial growth and hypertrophy in engineered heart muscle. Trends Cardiovasc Med, 24(1):7-13. [PubMed]
Tiburcy M, Didié M, Boy O, Christalla P, Doeker S, Naito H, Karikkineth BC, El-Armouche A, Grimm M, Nose M, Eschenhagen T, Zieseniss A, Katschinski D, Hamdani N, Linke WA, Yin X, Mayr M, Zimmermann WH. (2011) Terminal Differentiation, Advanced Organotypic Maturation, and Modeling of Hypertrophic Growth in Engineered Heart Tissue. Circ Res. 109:1105-1114. [PubMed]

Patents

Meyer T, Tiburcy M, Zimmermann WH. Lochplatte. 2016060314484000DE (Priority date: 3.6.2016).
Tiburcy M, Hudson JE, Zimmermann W.-H., 2015. International PCT patent. "Method for producing Engineered Heart Muscle (EHM)". WO 2015/025030 A1.
Hudson JE, Tiburcy M, Zimmermann W.-H., 2015. International PCT patent. “A method to direct differentiation of pluripotent stem cells into functional heart muscle”. WO 2015/040142 Al.